Crocs rallies on bullish outlook after company 'exceeded expectations across all metrics'
By Steve Gelsi
Footwear maker forecasts stronger-than-expected year ahead, after beating Q4 estimates
Crocs Inc.'s stock rallied Thursday after the footwear company said it expects to beat analyst estimates for its 2024 profit and also handed in stronger-than-expected fourth-quarter results.
Crocs (CROX) rose 2.4% to $110.95 in premarket trading, its highest level since last July.
Chief Executive Andrew Rees said the company booked a record year and that the fourth quarter "exceeded expectations across all metrics."
Crocs said it expects 2024 profit of $2.15 to $2.25 a share, ahead of the FactSet consensus of $2.05 a share, on revenue growth of 3% to 5%.
The Broomfield, Colo.-based company said its fourth-quarter net income for the three months ending Dec. 31 nearly doubled to $253.59 million, or $4.16 a share, from $137.74 million, or $2.20 a share, in the year-ago period.
Adjusted earnings in the latest quarter totaled $2.58 a share, well ahead of the analyst estimate of $2.37 a share.
Fourth-quarter revenue rose to $960.1 million from $945.2 million in the year-ago period. Analysts were looking for revenue of $958.4 million.
Chief Executive Andrew Rees said the company booked a record year and that the fourth quarter "exceeded expectations across all metrics."
Prior to Thursday's trades, Crocs stock had risen 16% in 2024, compared to a 5.7% gain by the Nasdaq COMP.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-15-24 0751ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks